Pharmerging Markets, Led By China, Expected To Keep Sales Growth "Strong" Through 2014, IMS Says
This article was originally published in PharmAsia News
Executive Summary
Growth in "pharmerging" markets is so strong it is likely to nearly offset lost sales from genericization of some of pharma's biggest products in the next two years, IMS Health said April 20
You may also be interested in...
China Approves Merck Serono Orphan Drug Kuvan; Paves Way For More Orphan Drug R&D
China's State FDA has approved Merck Serono's Kuvan (sapropterin) for orphan condition hyperphenylalaninemia in phenylketonuria or BH4 deficiency, a rare congenital metabolic disorder that increases blood phenylalanine levels. The approval underlines opportunities in the Chinese orphan drug market, says a leading Chinese expert
China Approves Merck Serono Orphan Drug Kuvan; Paves Way For More Orphan Drug R&D
China's State FDA has approved Merck Serono's Kuvan (sapropterin) for orphan condition hyperphenylalaninemia in phenylketonuria or BH4 deficiency, a rare congenital metabolic disorder that increases blood phenylalanine levels. The approval underlines opportunities in the Chinese orphan drug market, says a leading Chinese expert
Beyond BRIC: 'Pharmerging' Markets Loom If Pharma Is To Expand -IMS Study
Big Pharma needs to target emerging markets more aggressively - but not just the usual suspects. Brazil, Russia, India and China (BRIC) remain highly important, but in a March 16 report, IMS Health predicts that 17 countries, in total, will contribute 48 percent of annual market growth in 2013, up from 37 percent they contributed last year